News
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...
Silexion Therapeutics reports positive preclinical results for SIL204 in lung cancer, advancing dual-route administration and preparing for upcoming clinical trials.
Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Hosted on MSN5mon
Silexion Stock Hits Record Intraday Low After Pricing $5M ... - MSNShares of Silexion Therapeutics lost more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering ...
Hosted on MSN1mon
Silexion reports breakthrough in KRAS cancer therapy - MSNIn addition to these structural changes, Silexion Therapeutics Corp has made significant progress in its preclinical studies for SIL-204, a siRNA candidate aimed at treating KRAS-driven cancers.
Silexion Therapeutics completes a preclinical study on SIL204 for KRAS-driven cancers, anticipating results in coming days.
Ilan Hadar, Chairman and CEO of Silexion, commented: “2024 was a transformative year for Silexion, marked by our Nasdaq listing and the advancement of our clinical and preclinical pipeline.
Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Silexion's focus on RNAi technology for KRAS-driven cancers, especially its innovative approach to pancreatic cancer treatment, positions it as a potentially attractive acquisition target in this ...
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion has ...
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results